Shares of Vapotherm Inc (NYSE:VAPO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12-month consensus price objective of $25.50 for the company and are predicting that the company will post ($0.82) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Vapotherm an industry rank of 79 out of 256 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Zai Lab from a “buy” rating to a “hold” rating in a research report on Saturday, June 15th.
Shares of NYSE:VAPO traded down $0.14 during trading on Thursday, hitting $17.82. 1,665 shares of the company’s stock were exchanged, compared to its average volume of 44,665. The company has a debt-to-equity ratio of 1.01, a quick ratio of 5.34 and a current ratio of 6.35. Vapotherm has a 52-week low of $14.70 and a 52-week high of $24.63. The firm has a 50-day moving average of $20.16. The firm has a market capitalization of $319.58 million and a P/E ratio of -1.30.
Vapotherm (NYSE:VAPO) last released its earnings results on Tuesday, May 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.03. The business had revenue of $12.30 million for the quarter, compared to analysts’ expectations of $11.90 million. Research analysts expect that Vapotherm will post -3.15 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in the stock. Taylor Frigon Capital Management LLC acquired a new stake in Vapotherm during the second quarter valued at approximately $863,000. Marshall Wace North America L.P. purchased a new stake in Vapotherm in the first quarter worth about $161,000. Granite Investment Partners LLC purchased a new stake in Vapotherm in the first quarter worth about $811,000. Federated Investors Inc. PA increased its position in Vapotherm by 32.8% in the first quarter. Federated Investors Inc. PA now owns 398,435 shares of the company’s stock worth $7,829,000 after buying an additional 98,435 shares in the last quarter. Finally, Arnhold LLC increased its position in Vapotherm by 123.9% in the first quarter. Arnhold LLC now owns 25,434 shares of the company’s stock worth $500,000 after buying an additional 14,075 shares in the last quarter. 46.91% of the stock is owned by institutional investors.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
See Also: Market Capitalization in the Stock Market
Get a free copy of the Zacks research report on Vapotherm (VAPO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.